Kura Oncology (KURA) Cash from Investing Activities (2014 - 2026)

Kura Oncology (KURA) has 13 years of Cash from Investing Activities data on file, last reported at -$24.2 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$24.2 million, up 76.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $64.1 million (up 159.52% YoY), and the FY2025 annual result was -$13.1 million, up 87.11% from the prior year.
• Cash from Investing Activities rose to -$24.2 million in Q1 2026 per KURA's latest filing, from -$64.6 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $94.0 million in Q3 2025 and troughed at -$101.4 million in Q1 2025.
• A 5-year average of -$5.3 million and a median of $8.6 million in 2023 frame the typical range for Cash from Investing Activities.
• On a YoY basis, Cash from Investing Activities climbed as much as 432.01% in 2024 and fell as far as 956.65% in 2024.
• A 5-year view of Cash from Investing Activities shows it stood at -$47.3 million in 2022, then jumped by 189.17% to $42.2 million in 2023, then tumbled by 325.04% to -$95.0 million in 2024, then soared by 31.97% to -$64.6 million in 2025, then surged by 62.49% to -$24.2 million in 2026.
• Business Quant data shows KURA's Cash from Investing Activities at -$24.2 million in Q1 2026, -$64.6 million in Q4 2025, and $94.0 million in Q3 2025.